许多肿瘤组织同时表达表皮生长因子受体(epidermalgrowth factor receptor,EGFR)及其配体,EGFR及其配体网络已经明确为肿瘤治疗的重要靶点。表皮生长因子受体酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)以其高选择性和低毒性的优势在肿瘤临床治疗中令人瞩目[1]。同样很多问题也随着临床研究的不断深入逐步浮出水面,EGFR抑制剂停药标准问题就是其中之一。当前临床TKI停药标准被 Many tumor tissues express epidermal growth factor receptor (EGFR) and their ligands simultaneously, and EGFR and its ligand network have been identified as important targets for tumor therapy. Epidermal growth factor receptor tyrosine kinase inhibitor (tyrosine kinase inhibitor, TKI) for its high selectivity and low toxicity in the clinical treatment of tumors is remarkable [1]. As many of the same problems have gradually surfaced with the continuous deepening of clinical research, EGFR inhibitor withdrawal criteria is one of them. The current clinical TKI withdrawal criteria were